Olfazumab

Related products

• 

  Breast cancer , Late childhood neuroblastoma

  Melphalan

  【Product name】Alkeran

  [English common name]Melphalan

  [Chinese common name]Melphalan

  [English name]Melphalan HCl, Melphalan 2HCl, l-phenylalanine mustard

  [Chinese other name]Melfal, Melphalan, cancer Kyan, Milfair

  [Indications] This product can be used with a variety of tumors, in single chemotherapy and combination chemotherapy,Multiple myelomaThe drug of choice. CorrectSpermato cell tumor,Breast cancer,Ovarian cancer,Chronic leukemia,Polycythemia vera,Malignant lymphoma,Late childhood neuroblastoma,Thyroid cancereffective. Arterial infusion for the treatment of limb malignancies such as malignant melanoma, soft tissue sarcoma and osteosarcoma has a good effect, even for the treatment of certain autoimmune diseases and to prevent rejection during organ transplantation.

  【Dosage】
  Multiple myeloma:
  A typical dose is 0.15 mg per kilogram of body weight per day, taken in four divided doses, and repeated for six weeks. Prolonged treatment for those who respond to treatment will not change the effect. The combination of melphalan and prednisone may be more effective than single use.
  Ovarian adenocarcinoma:
  A typical treatment regimen is 0.2 mg per kilogram of body weight per day for five days, repeated every 4 to 8 weeks or when the peripheral blood is restored; the dose should be reduced when bone marrow toxicity occurs.
  Advanced breast cancer:
  Oral melphalan daily 0.15 mg per kilogram of body weight or 6 mg per square meter of body surface area for a total of 5 days, repeated treatments every six weeks, can also be treated with intravenous melphalan.
  True erythrocytosis:
  Induction of remission, use 6 to 10 mg daily for 5 to 7 days, then 2 to 4 mg per day until the symptoms can be satisfactorily controlled. The maintenance dose can be 2 to 6 mg per week. Care must be taken during the patient. The hematology control is performed on the ground, and the dose is appropriately adjusted based on the blood cell count result.
  Patients with renal insufficiency:
  Based on current pharmacokinetic data, oral melphalan is not recommended for patients with moderate to severe renal insufficiency, but the initial dose should be carefully reduced.

  [Storage]Store in a dark, cool, dry place.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Chronic myelogenous leukemia (CML) , Chronic myeloid leukemia

  Homoharringtonine

  【Product name】Homobarringtonie, Synribo

  [English common name]Homoharringtonine

  [Chinese common name]Homoharringtonine

  [English name]Ceflatonin

  [Chinese other name]High crude

  [Indications] for all types of acute non-lymphocytic leukemia,Myelodysplastic syndrome(MDS),Chronic myeloid leukemiaandPolycythemia veraThere is also a certain effect.

  【Dosage】
  1. Adult commonly used amount: intravenous drip, 1 ~ 4mg (1 ~ 4) per day, add 5% glucose injection 250 ~ 500ml, slowly drip for more than 3 hours, 4 to 6 days for a course of treatment, interval 1 Repeat the medication for ~2 weeks.
  2. Commonly used amount in children: intravenous drip, daily weight of 0.05 ~ 0.1mg / kg, 4 to 6 days for a course of treatment.

  [Storage] shading, sealed, and kept in a cool place.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Chronic myelogenous leukemia (CML) , Chronic myeloid leukemia

  Busulfan

  [product name] Myleran, Busilvex, Busulfex Bai Shufei

  [English common name]busulfan

  [Chinese common name] Bai Xiaoan

  [English name]Busulphan, Tetramethylene bis(methanesulfonate)

  [Chinese other name]Malilan, White Blood Fuen

  [indications]
  Bai Xiao'an tablets: This product is mainly suitable forChronic myeloid leukemiaThe chronic phase is not effective for patients with a lack of Philadelphia chromosome Ph1. It can also be used to treat essential thrombocytosis.Polycythemia veraSuch as chronic myeloproliferative diseases.
  Baixiao'an injection: This product is suitable for combined with cyclophosphamide as a pretreatment protocol for hematopoietic progenitor cells of chronic myeloid leukemia.

  【Dosage】
  Baixiao'an tablets: This product is commonly used in adults: chronic myeloid leukemia, total daily 4 ~ 6mg / m2, once a day. If the number of white blood cells drops to 20 × 109 / L, it is necessary to stop the drug as appropriate. Or give a maintenance amount of 1 to 2 mg per day or every other day to maintain a white blood cell count of about 10 × 109 / L.
  Baixiao'an injection: This product should be administered through the central venous catheter. Each dose requires infusion for 2 hours, and every 6 hours for 4 consecutive days, a total of 16 times.

  [Storage]
  Buchanan tablets: sealed and kept in a cool place.
  Baixiao'an injection: 2 ° C ~ 8 ° C

  【Tips】Part of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctor's face diagnosis. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Chronic myeloid leukemia , Gastrointestinal stromal tumor (GIST)

  Imatinib

  【Product name】Imatinib

  [English common name]GLEEVEC

  [Chinese common name]Imatinib

  [English name]Imatinib intermediates, imatinib

  [Chinese other name]Imatinib intermediate, imatinib

  [indications]
  Imatinib mesylate capsule: for treatmentChronic myeloid leukemia(CML) chronic phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy; malignancy that cannot be surgically removed or metastasizedGastrointestinal stromal tumor (GIST)patient.
  Imatinib mesylate tablets: for the treatment of chronic chromosome patients with chronic myeloid leukemia (CML) in Philadelphia, in the blast phase, accelerated phase, or chronic phase after failure of alpha-interferon therapy.
  Adult patients for the treatment of malignant gastrointestinal stromal tumors (GIST) that cannot be removed and/or metastasized.

  【Dosage】
  Imatinib mesylate capsule: starting dose: for patients with blast crisis and accelerated phase of chronic myeloid leukemia, the recommended dose of imatinib mesylate is 600 mg/day; for chronic patients who have failed interferon therapy, and For patients with malignant gastrointestinal stromal tumors (GIST) who cannot be surgically removed or metastasized, the recommended dose is 400 mg/day, which is taken once a day. It is advisable to take the medicine at mealtime and drink a large glass of water. It should be taken continuously.
  If the blood picture permits, there is no serious adverse drug reaction, the dose can be considered to increase from 400mg / day to 600mg / day, or from 600mg / day to 800mg / day (400mg, divided into 2 times) in the following cases: disease progression, treatment A satisfactory hematologic response was not obtained after at least 3 months, and the hematologic response that had been obtained disappeared again.
  The dose must be adjusted in the following cases: if a serious non-hematologic adverse reaction (such as severe water retention) occurs during the treatment, the drug should be discontinued until the adverse reaction disappears, and then the dose is adjusted according to the severity of the adverse reaction.
  Dose adjustment in severe liver toxicity: If the bilirubin rises more than 3 times the upper limit of the normal range or the transaminase rises more than 5 times the upper limit of the normal range, the drug should be discontinued until the above indicators fall to 1.5 or 2.5 times the upper limit of the normal range. the following.
  Adjustment of dose during neutropenia or thrombocytopenia: accelerated or blast phase: if severe neutrophils and thrombocytopenia occur (neutrophils <0.5×109/L and/or platelets<10×109/L The recommended dose is reduced to 400 mg / day. If the blood cells continue to decrease for 2 weeks, further reduce the dose to 300 mg / day, if the blood cells continue to decrease for 4 weeks, it is advisable to stop the drug until neutrophils ≥ (greater than or equal to ) 1.0 × 109 / L and platelets ≥ (greater than or equal to) 20 × 109 / L. When used again, the dose is 300 mg / day.
  Patients with chronic phase after failure of α-interferon therapy: neutrophils <1.0×109/L and/or platelets <50×109/L should be discontinued, only in granulocyte ≥ (greater than or equal to) 1.5 When x109/L and platelet ≥ (greater than or equal to) 75×109/L, the dosage is 400 mg/day. If the neutrophils or platelets are reduced to the above values, the dosage will be restored. Reduced to 300 mg / day.
  Children and adolescents: There are no clinical data on the safety and efficacy of imatinib mesylate in patients under 18 years of age.
  Dosage in patients with liver failure: The plasma concentration of imatinib mesylate can be increased in patients with liver damage, so these patients should be cautious when using this drug. There is no liver damage in patients with liver damage. Nie's clinical data, no suggestion for dose adjustment.
  Renal failure and dose in elderly patients: creatinine clearance is known to decrease with age, and age has no significant effect on the pharmacokinetics of imatinib mesylate, as it has not been performed in patients with impaired renal function. Clinical trials, so it is not possible to propose a dose adjustment.
  Imatinib mesylate tablets: starting dose: The initial treatment should be performed by a physician with experience in treating chronic myelogenous leukemia or GIST.
  The product should be taken orally, and it is advisable to take the medicine while eating and drink a large glass of water. Usually adults once a day. Children and adolescents take it once or twice a day (morning and evening).
  Patients (children) who cannot swallow tablets can disperse the tablets in water or apple juice. It is recommended that pregnant and lactating women avoid contact with skin or eyes when inhaling capsules, or inhalation (see pregnant and lactating women), and wash hands immediately after touching open capsules.
  - therapeutic dose of CML patients
  adult
  The recommended dose for patients in the chronic phase is 400 mg/day, and for the blast phase and accelerated phase, it is 600 mg/day.
  As long as it is effective, it should be taken continuously.
  If the blood picture permits, there is no serious adverse drug reaction, the dose can be considered to increase from 400 mg / day to 600 mg / day, or from 600 mg / day to 800 mg / day (400 mg, orally, 2 times) Taking): The disease has not been able to obtain a satisfactory hematologic response after at least 3 months of treatment, and the hematological response has disappeared.
  Children and adolescents over 3 years old
  So far, children have limited experience in medication. According to the adult dose, the recommended daily dose is: chronic phase 260mg / m2 (maximum dose: 400mg), accelerated phase and blast phase 340mg / m2 (maximum dose: 600mg), the daily recommended dose for children, the calculated dose is generally Should be close to or around 100mg, the dose for children under 12 should generally be as close as possible or around 50mg. There is no experience in treating children under 3 years of age.
  - therapeutic dose of GIST patients
  For patients with malignant GIST who cannot be removed and/or metastasized, the recommended dose for this product is 400 mg/day.
  A satisfactory response was not obtained after treatment. If there were no adverse drug reactions, the dose could be considered to increase from 400 mg/day to 600 mg/day. Treatment time:
  For patients with GIST, the product should be treated continuously unless the condition progresses.

  [Storage]
  Imatinib mesylate capsule: should be kept below 30 °C.
  Imatinib mesylate tablets should be kept below 30 °C.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.